Telix Pharmaceuticals Reports 19% Q3 Revenue Growth, Reaffirms FY2026 Guidance
Telix Pharmaceuticals reported group revenue growth of 19% for the quarter ended September 30, 2026, and reaffirmed its full-year 2026 revenue guidance.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.